Baguley, B. C., 115, 249, 287
Balzarini, J., 195
Barraclough, R., 311
Bentrem, D. J., 401
Bertoni, F., 297
Bharadwaj, T. P. R., 101
Biondi, C., 437
Bishayee, A., 41
Bloomer, W. D., 345
Bologna, M., 17
Bombardelli, E., 145, 471
Bonanno, G., 471
Borselli, C., 421
Bosserhoff, A. K., 55
Broggini, M., 297
Brower, S. T., 489
Buettner, R., 55

Cabral, F., 455
Cañete, M., 447
Cao, S., 91
Capaccioli, S., 437
Capelli, G., 145
Carbone, E., 339
Caspani, G., 297
Chambers, A. F., 161
Chandra, J., 455
Chatterjee, M., 41
Chaudhri, G., 331
Chen, B., 133
Chen, S.-H., 489
Chong, D., 133
Cianchi, F., 437
Codegoni, A. M., 297
Colella, G., 297
Colosetti, P., 375
Conway, R. M., 331
Cortesini, C., 437
Cowan, K. H., 153
Cross, H. S., 77

D'Andrea, E., 529
D'Incalci, M., 297
Danieli, B., 145
Davis, S. A., 303
De Celrcq, E., 195
De Vincenzo, R., 145
Ding, L., 287
Distefano, M., 145, 471
Divino, C. M., 489
Domínguez, V., 447
Dréau, D., 55

Ellinger, A., 77

Faraone, S., 529
Ferlini, C., 145, 471
Festuccia, C., 17
Ficari, F., 437
Finance, C., 375
Finlay, G. J., 115, 249
Fodor, I., 133
Fujiwara, N., 497
Funahashi, Y., 319
Fusco, A., 421

Gaggini, C., 145
Galettis, P., 287
Galffy, G., 187
Gatter, K. C., 205
Georgoulias, V., 205
Giatromanolaki, A., 205
Gitsch, G., 367
Giunciuglio, D., 17
Gnainsky, J., 255
Gomes-Marcondes, M. C. C., 359
Gopinath, P. M., 101
Gougoumas, D., 409
Grassi, L., 297
Gridley, D. S., 133
Guerra, F., 17
Gulisano, M., 265
Guo, B., 91

Haddad, G. G., 287
Hamilton, J. W., 303
Hanibuchi, M., 219
Hardell, L., 539
Harris, A. L., 205
Hatse, S., 195
Hayashi, K., 461
Hirabayashi, K., 497
Hofer, H., 77
Holder, W. D., 55
Hotfilder, M., 513
Hwu, W.-J., 529

James, W. I., 505
Janoff, A. S., 273
Ji, M., 345
Jordan, V. C., 401
Juarranz, A., 447

Kageyama, K., 479
Kaltreider, R. C., 303
Kannan, K., 101
Kataoka, S., 71
Khan, S. H., 345
Kim, H. S., 9
Kitoh, K., 319
Knüpfer, H., 523
Knüpfer, M. M., 523
Kobayashi, E., 71
Komatsu, F., 213
Koukourakis, M. I., 205
Koyama, K., 281
Kozu, A., 71
Kuiper, C. M., 383

Langridge, W. H. R., 133
Lariviere, J. P., 303
Leffert, J. J., 529
Leodolter, S., 367
Li, G.-M., 393
Li, J., 133
Li, W., 243
Liel, Y., 255
Linde, A., 539
Lingwood, C., 33
Liu, J.-W., 479

Madigan, M. C., 331
Mancuso, S., 145, 471
Manduca, P., 17
Marchal, S., 375
Marsh, J. C., 529
Marshall, E. S., 115
Masters, G. R., 273
Mayhew, E., 273
Mazzei, T., 437
Mazzoni, P., 437
McConkey, D. J., 455
McKeage, M. J., 287
Melillo, R. M., 421
Merlin, J.-L., 375
Mineura, K., 513
Mini, E., 437
Miwa, N., 479
Miyoshi, Y., 125
Mohammed, K. A., 187
Monden, M., 281
Morazzoni, P., 145
Morganti, M., 437
Mori, T., 513
Multani, A. S., 455
Munirajan, A. K., 101
Murakami, K., 461
Murata, J., 461

Naesens, L., 195
Nagao, N., 479
Nakamura, Y., 125, 281, 513
Nam, S. M., 9
Napoli, C., 437
Nasca, R., 339
Näsman, Å., 539
Nasreen, N., 187
Nervi, A. M., 303
Ng, C. C., 281
Nguyen, J., 273
Nishimura, N., 219
Nishioka, Y., 219
Nokihara, H., 219
Nordström, M., 539
Nozawa, S., 71, 233

Obermair, A., 367
Ogasawara, M., 461
Oie, S., 71
Ojima, I., 471
Okamura, S., 281

Pacini, P., 265
Pacini, S., 265
Papadopoulou, M. V., 345
Pappas, I. S., 409
Parajuli, P., 219
Park, Y. S., 9
Pathak, S., 455
Penfold, P. L., 331
Pesce, C. A., 303
Peterlik, M., 77
Peters, G. J., 383
Pierelli, L., 471
Pitzer, C., 85
Pizzorno, G., 529
Pollak, J., 529
Polo, S., 447
Portella, G., 421
Pradheepkumar, C. P., 225
Preiß, R., 513

Quattrone, A., 437

Saiki, I., 461
Salem, R. R., 529
Salvatore, D., 421
Sane, S., 455
Santoro, M., 421
Sanz, C., 447
Sartorelli, A. C., 429
Scambia, G., 145, 471
Schiebel, I., 367
Schloss, L., 539
Schmid, B. C., 367
Schmitt, S., 505
Schupsky, J. J., 273
Schwartz, B., 255
Screnci, D., 287
Segers, C., 195
Semba, T., 319
Sen, S., 455
Shanmugam, G., 101, 225
Shany, S., 255
Shen, D., 63
Shen, F., 243
Sinha, B. K., 153
Sivridis, E., 205
Smirnoff, P., 255
Sone, S., 219
Song, K., 153
Sonoda, J., 319
Stassar, M. J. J. G., 85
Stimpfl, M., 367
Stockert, J. C., 447

Takahashi, M., 71
Takei, Y., 281
Takesue, H., 497
Tamada, Y., 233
Tannock, I. F., 179
Taylor, S. L., 311
Teti, A., 17
Tharu, R., 101
Thompson, T. C., 1
Timiryasova, T. M., 133
Tokino, T., 125, 513
Toledo, M. T., 359
Tonelli, F., 437
Tong, D., 367
Tong, W.-M., 77
Tóth, K., 91
Tsiftsoglou, A. S., 409
Tsuchida, N., 101

Udagawa, Y., 71
Ueda, K., 125
Utsugi, T., 219

Vadgama, J. V., 63
van der Wilt, C., 383
Vecchio, G., 421
Vendrell, V. D., 447
Verbeken, E., 195
Villanova, I., 17
Villanueva, A., 447
Vitagliano, D., 421
Vizirianakis, I. S., 409

Waer, M., 195
Wakabayashi, T., 319
Wang, J. H., 505
Ward, M. J., 187
Warren, A. J., 303
Watatani, M., 125
Weber, G., 243
Weinberg, E. D., 109
White, R. L., 55
Wu, W., 461

Xiao, H. H., 429
Xu, J., 429

Yamaura, T., 461
Yano, J., 497
Yano, S., 219
Yin, B.-b., 91
Yoshida, S., 213
Yoshimatsu, K., 319

Zeillinger, R., 367
Zhuang, L., 287
Zöller, M., 85

Bax dimerization, 91
bcl-2, 205
Bioreductive drugs, 345
Blood, 55
Bone metastasis, 17
Borrelidin, 319
BRCA1, 63
BRCA2, 63
Breast, 169
Breast cancer, 265, 311, 401, 505
Breast Cancer Information Core (BIC), 55

Caco-2 cells, 77
Cancer, 9, 169, 393, 523
Cancer chemotherapy, 303
Carbohydrate epitope, 233
Carboplatin, 115
Caspase, 91
Caspase-3, 71
Cationic liposome, 497
CD40, 339
cDNA cloning, 409
c-erbB-2, 311
Cell cycle, 243, 249, 297
Cell cycle block, 471
Cell death, 455
Cell proliferation, 169
Cell transformation, 169
Chemical carcinogenesis, 169
Chemotherapy, 345
CHO mutant cell lines, 455
Choriocarcinoma, 195
cis-Platinum, 153
Cleistanthin A, 225
Clinical, 115
Colchicine analogs, 145
Colon cancer, 461
Colorectal cancer, 77, 255
Colorectal carcinoma, 437
Combination gene therapy, 153
Competitive PCR, 311
Cremophor EL, 273
Cyclin D1, 77
CYP, 523
Cytochrome c, 91
Cytokinetics, 115
Cytotoxicity, 243, 339, 471

Development, 169
Diethylnitrosamine, 41
Differential display, 85, 281
Differential expression, 85
Differentiation, 331, 409, 421, 429
1a,25-Dihydorxyvitamin D₃, 77
DNA methylation, 255
Docetaxel, 471
Doubling time, 115
Doxorubicin, 9, 249
Drug interactions, 287
Drug resistance, 153
Drug response, 91

Early antigen (EA), 539
EBNA-1, 539
Electromagnetic fields, 265
ELISA, 55
Endometrial adenocarcinoma, 205
Epidermal growth factor receptor, 77
Epithelial markers, 367
Epstein-Barr virus (EBV), 539
Estrogen, 255
Estrogen receptor, 169
Evaluation of detection methods, 367
Exhausts, 539
Expression, 409
Extracellular domain, 513

fhit, 101
Fluoroquinolone, 375
5-Fluorouracil, 437
Folylpolyglutamate synthetase, 437
 

hCAR, 513
HeLa cells, 447
Hematopoietic progenitors, 471
Hemofiltration, 529
Hepatocarcinogenesis, 41
HL-60 leukemia, 429
HSP70 multiple gene family, 429
Human breast epithelial cell, 169
Human cancer cells, 145
Human myeloma 8226 cells, 243
Human ovarian carcinoma OVCAR-5 cells, 243
Human T-lymphotropic virus type 1 (HTLV-1), 213
Human tumor models, 273
Hypoxia, 319IFN-a2b, 55

IL-2, 55
Immunoblotting, 331
Immunocytochemistry, 311
Immunocytolytic factor, 489
Immunoliposome, 9
Immunomagnetic separation, 367
Immunotherapy, 55
IMP DH, 243
In situ hybridization, 311
In vivo model, 319
Infectivity, 513
Inhaled iron withholding, 109
Interleukin-8, 187
Interleukins, 523
Intra-arterial chemotherapy, 529
Invasion, 461, 471
IP₃, 243

Ki67, 169
Killer inhibitory receptor, 339

Lobules, 169
Low molecular weight proteins, 85
Lung cancer, 109, 219
Lymphocytes, 489
Lymphokine-activated killer (LAK), 213

Marker, 55
Matrix metalloprotease, 471
Matrix metalloproteinase (MMP), 461
MCF-10F, 169
MDA-MDB-435 breast cancer cell line, 303
MDS, 101
Mechanisms, 345
MEL cells, 409
Melanoma, 55, 339
Melanoma-inhibitory activity protein (MIA), 55
Mesothelioma, 187
Metalloproteinase-9, 17
Metastasis, 461, 471
Metastatic inefficiency, 161
Metastatic liver cancer, 497
MHC class I, 339
Microsatellites, 297
Mismatch repair, 393
Mitochondrial chaperone HSP70, 429
Monoclonal antibody, 233
MT-2, 213
MTA, 383
Mucins, 233
Multidrug resistance (MDR), 145, 219, 303, 375
Multidrug resistance-associated protein, 375
Mutation(s), 63, 297

Natural killer cell inhibitory receptor, 213
Natural killer cells, 339
Necrosis, 447
Neoplasms, 265
Neurotoxicity, 287
NK-92, 213
Nolatrexed, 383
Nucleotide analogue, 195
Nude mouse model, 187

Olfoxacin, 375
Ovarian cancer, 297
Ovarian carcinoma, 153, 233
Oxazaphosphorines, 523

Quantification, 319
Quercetin, 243

Raloxifene, 401
Raltitrexed, 383
ras, 421
Rats, 41
RD/TE-671 cells, 409
Reactive oxygen species, 471
Renal cell carcinoma, 85
Resistance, 437
RET, 421
Reverse transcription-polymerase chain reaction, 233
Ribavirin, 243

S5 ribosomal protein, 409
SCID mice, 505
Sensitivity testing, 115
Signal transduction, 243
SKG-3a, 71
SKG-3b, 71
Social isolation, 461
Steroid receptors, 255

T98G, 125
Tamoxifen, 401
Target sensitivity, 9
TAS-103, 219
Tax-18, 455
Tax-2-4, 455
Taxanes, 287, 471
Taxol, 273
Telomere erosion, 455
Therapeutics, 273
Thiocolchicone, 145
THNLA-1, 345
Threshold, 55
Thymidylate synthase, 383, 437
Thyroid, 421
Timing of surgery relative to menstrual cycle, 161
Tobacco smoking, 109
Topoisomerase II, 249, 375
Topoisomerase inhibitor, 219
Toxicity, 273
TRAP-2, 85
TRK, 421
a- and b tubulin, 145
Tumor, 133
Tumor-associated antigen(s), 9, 85
Tumor dormancy, 161
Tumor necrosis factor-a (TNF-a), 461
Tumor physiology, 179
Tumor suppressor genes, 101
Tumorigenesis, 421

Urokinase, 17
Urokinase-type plasminogen activator (u-PA), 461
Vaccina virus, 133

Vaccine, 55
Vanadium, 41
Vasodilating drugs, 179
VEGF, 319
Venous isolation, 529
Videomicroscopy, 161
Vitamin D, 255, 265

Walker 256 tumor, 359

Xenobiotic biotransforming enzymes, 41
Xenografts, 273

Zinc(II)-phthalocyanine, 447